Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Zai Lab gains on early data from lung cancer drug study

** U.S.-listed shares of China-based drug developer Zai Lab
 9688.HK  rise 10.6% to $32 premarket
    ** Co reports data from early-stage study testing its
experimental drug to treat previously treated patients with a
type of lung cancer
    ** Says its drug, ZL-1310, helped either remove all signs of
cancer from the body or significantly reduce the size of tumor
in 74% of patients with recurrent extensive-stage small cell
lung cancer
    ** ZL-1310 belongs to a class of drugs called antibody-drug
conjugates, which are targeted cancer therapies that function
like "guided missiles" against tumor cells while sparing healthy
ones
    ** Stock up ~6% so far this year as of last close

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))

Recent news on Zai Lab

See all news